Heart inflammation risk after COVID-19 vaccine.
作者信息
Szarpak Lukasz, Pruc Michal, Koda Mariusz, Chirico Francesco
机构信息
Institute of Research Outcomes, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland.
Research Unit, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland.
出版信息
Cardiol J. 2021;28(6):1001-1002. doi: 10.5603/CJ.a2021.0161. Epub 2021 Dec 13.
Abstract
摘要
相似文献
1
Heart inflammation risk after COVID-19 vaccine.新冠疫苗接种后的心脏炎症风险。
Cardiol J. 2021;28(6):1001-1002. doi: 10.5603/CJ.a2021.0161. Epub 2021 Dec 13.
2
Arrhythmias after COVID-19 Vaccination: Have We Left All Stones Unturned?新冠病毒疫苗接种后心律失常：我们是否已彻底研究过所有问题？
Int J Mol Sci. 2023 Jun 20;24(12):10405. doi: 10.3390/ijms241210405.
3
Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants.针对 SARS-CoV-2 及其变体的多样化疫苗平台。
Expert Rev Vaccines. 2022 Jan;21(1):47-67. doi: 10.1080/14760584.2022.1997601. Epub 2022 Jan 11.
4
[Inflammation of BCG Inoculation Site Scar after the First Dose of an Anti-SARS-CoV-2 mRNA Vaccine].[首剂抗SARS-CoV-2 mRNA疫苗接种后卡介苗接种部位瘢痕的炎症反应]
Acta Med Port. 2023 Jul 3;36(7-8):511-514. doi: 10.20344/amp.16971. Epub 2022 Sep 19.
5
Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models.新型冠状病毒疫苗 mRNA 对不同种属小鼠动物模型诱导心肌炎的影响。
Int J Mol Sci. 2023 Mar 6;24(5):5011. doi: 10.3390/ijms24055011.
6
Letter to the editor: More data on vaccine efficacy/effectiveness of COVID-19 vaccines against asymptomatic SARS-CoV-2 infection.致编辑的信：关于新冠病毒疫苗对无症状SARS-CoV-2感染的效力/效果的更多数据
Euro Surveill. 2021 Sep;26(35). doi: 10.2807/1560-7917.ES.2021.26.35.2100826.
7
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
8
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.智利科兴和国药疫苗接种后动态 IgG 血清阳性率：哨点监测研究。
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
9
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.针对 COVID-19 mRNA 疫苗 BNT162b2 作为灭活 SARS-CoV-2 病毒疫苗异源加强针的疫苗有效性的证据综合和汇总分析。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2165856. doi: 10.1080/21645515.2023.2165856. Epub 2023 Feb 1.
10
Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.在首次发生免疫性血小板减少性紫癜后成功进行mRNA SARS-CoV-2疫苗再次接种。
Platelets. 2022 May 19;33(4):652-653. doi: 10.1080/09537104.2022.2044463. Epub 2022 Feb 28.
引用本文的文献
1
Systematic review with meta-analysis of mid-regional pro-adrenomedullin (MR-proadm) as a prognostic marker in Covid-19-hospitalized patients.系统评价与荟萃分析显示，中段促肾上腺髓质素（MR-proadm）作为新冠病毒感染住院患者的预后标志物。
Ann Med. 2023 Dec;55(1):379-387. doi: 10.1080/07853890.2022.2162116.
2
COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte.新型冠状病毒肺炎：免疫反应、突变和应对措施的研究进展。
J Infect Public Health. 2023 Feb;16(2):233-249. doi: 10.1016/j.jiph.2022.12.019. Epub 2022 Dec 29.
本文引用的文献
1
Variant lambda of the severe acute respiratory syndrome coronavirus 2: A serious threat or the beginning of further dangerous mutations.严重急性呼吸综合征冠状病毒2的变异毒株拉姆达：严重威胁还是进一步危险变异的开端？
Cardiol J. 2022;29(1):176-177. doi: 10.5603/CJ.a2021.0121. Epub 2021 Oct 13.
2
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization.大型医疗机构中接种新冠疫苗后的心肌炎。
N Engl J Med. 2021 Dec 2;385(23):2132-2139. doi: 10.1056/NEJMoa2110737. Epub 2021 Oct 6.
3
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.以色列接种 BNT162b2 mRNA 疫苗后出现心肌炎。
N Engl J Med. 2021 Dec 2;385(23):2140-2149. doi: 10.1056/NEJMoa2109730. Epub 2021 Oct 6.
4
Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data - United States, March 2020-January 2021.基于医院管理数据的 2020 年 3 月-2021 年 1 月期间美国 COVID-19 与心肌炎之间的关联
MMWR Morb Mortal Wkly Rep. 2021 Sep 3;70(35):1228-1232. doi: 10.15585/mmwr.mm7035e5.
5
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.BNT162b2 mRNA 新冠疫苗在全国范围内使用的安全性。
N Engl J Med. 2021 Sep 16;385(12):1078-1090. doi: 10.1056/NEJMoa2110475. Epub 2021 Aug 25.
6
Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis.20岁以下人群感染新冠病毒后发生心肌炎的风险：一项基于人群的分析。
medRxiv. 2022 Mar 21:2021.07.23.21260998. doi: 10.1101/2021.07.23.21260998.
7
Myocardial infarction in the shadow of COVID-19.新冠疫情阴影下的心肌梗死
Cardiol J. 2020;27(5):478-480. doi: 10.5603/CJ.2020.0152.
8
Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients.心肌损伤的确定可改善 COVID-19 患者的风险分层并预测其死亡率。
Cardiol J. 2020;27(5):489-496. doi: 10.5603/CJ.a2020.0089. Epub 2020 Jun 26.
9
COVID-19 challenge for modern medicine.现代医学面临的 COVID-19 挑战。
Cardiol J. 2020;27(2):175-183. doi: 10.5603/CJ.a2020.0055. Epub 2020 Apr 14.
Zotero 插件